Speciality: Hematology
Description:
A warm welcome to all the medical professionals in this memorable scientific session of thromboprophylaxis in medical settings. We have Dr. Ashish Bhalla, Dr. Tobias Tritschler and Dr. Bharat Jagiasi to lead this session.
The primary subject of discussion in this webinar is the increasing risk of hospital acquired deep vein thrombosis and pulmonary embolism among the patients. Get a broader knowledge of the above mentioned topics by learning about different instances.
Venous thromboembolism is the most common cause of death observed in surgical patients. Thromboprophylaxis is the mechanical method to promote venous outflow from the legs and antithrombotic drugs. This can be an effective means of reducing morbidity and mortality in the patients with hospital acquired deep vein thrombosis.
Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Doctors say lung cancer is still the deadliest cancer, but hope is growing
2.
Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.
3.
FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.
4.
The FDA has approved momelotinib for use in myelofibrosis patients who also have anemia.
5.
Virtual Reality Travel Reduces Cancer Pain.
1.
Clinical Decision-Making in Oligometastatic Cancer: A Case-Based Perspective
2.
Iron Homeostasis Throughout the Female Lifespan
3.
The Benefits and Side Effects of Vidaza Syndrome
4.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
5.
Exercise Rehabilitation in Hematologic Disease Survivorship
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
3.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
4.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
Preventing Blood Clots: The Importance of Venous Thromboembolism Management
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation